Pain Specialists

  • It is estimated that 2% to 5% of all patients who undergo surgery will develop a Surgical Site Infection (SSI). These infections are associated with added morbidity, including prolonged hospitalisation by 2 weeks, 5 times the risk of readmission, an increase in average health care costs of up to $26,000 per patient, and twice the risk of death.[1]
FloraSeal®
  • FloraSeal has been shown to trap and immobilise bacteria that may cause infection to the patient. It rapidly and powerfully kills gram-positive and gram-negative bacteria.[2]
  • FloraSeal effectively reduces microbial colonisation within 15 minutes and maintains a low microbial colonisation throughout the 24 hours after application, has the same efficacy when being used with or without an antimicrobial surgical incise drape, and mitigates microorganisms more effectively than an antimicrobial surgical incise drape alone.[3]

1. Towfigh, S., Cheadle, W. G., Lowry, S. F., Malangoni, M. A., & Wilson, S. E. (2008). Significant reduction in incidence of wound contamination by skin flora through use of microbial sealant. Archives of surgery (Chicago, Ill.:1960), 143(9), 885–891.

2. Prince, D., Kohan, K., Solanki, Z., Mastej, J., Prince, D., Varughese, R., & Patel, M. (2017). Immobilization and death of bacteria by Flora Seal microbial sealant. Int J Pharm Sci Invent, 6(6), 45-49.

3. Data on File. HB Fuller - Medical Adhesives Technology

SurgiSeal® Topical Skin Adhesive is a high purity, antimicrobial, liquid topical skin adhesive that can replace sutures for incision or laceration repair.

SurgiSeal® is the only topical skin adhesive in the world to receive FDA 510K Clearance in demonstrating inhibition of gram-positive and gram-negative bacteria growth.[1]

SurgiSeal® provides the optimal balance between strength and flexibility. In replacing sutures for incision or laceration repair, it can save time, provide a flexible, water-resistant, protective coating, and eliminate the need for suture removal.

FloraSeal®

1. SurgiSeal IFU: Due to the anhydrous property of the SurgiSeal adhesive, gram+ and gram- bacteria which become incorporated within the adhesive upon application, are not expected to grow.

The Accurian™ Radiofrequency Ablation (RFA) platform combines proprietary hardware design and quad core processing, resulting in sophisticated algorithms that manage power and control temperature during ablation surgery. The Accurian™ ablation therapy platform has been extensively tested for lasting reliability and is upgrade-ready for the future.

Accurian™

PROCEDURES

  • Knee OA/Pain
  • Hip OA/Pain
  • Shoulder OA/Pain
  • Cervical OA/Pain
  • Thoracic OA/Pain
  • Lumbar OA/Pain
  • Sacroiliac Joint OA/Pain
Accurian™ in knee procedures
Accurian™ in thoracic spinal procedures
Accurian™ in sacral spine procedures

Spine Stimulators

  • Reduced risk of thermal damage to transvenous leads[4] (in Pacemaker changes)
  • Precise dissection with less risk of thermal and mechanical lead damage[4,5,6]
  • Reduced ventricular oversensing or other CIED interactions[4,5] (in Pacemaker changes)
  • Shown to decrease procedure time by up to 40%, decrease lead damage events, and avoid prolonged hospital stays, resulting in an average cost savings of $155 per case[7] (in Pacemaker changes)
PlasmaBlade™

PROCEDURES

  • Spine Stimulator changeouts
  • Spine Stimulator replacements
  • Spine Stimulator upgrades

4. Wilkoff BL, Aurricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, Hayes DL, et al. HRS/EHRA expert consensus on the monitoring of cardiac electronic implantable devices (CIEDs) description of techniques indications, personnel, frequency, and ethical considerations. Heart Rhythm. 2008; 5: 907-925.

4. Wilkoff BL, Aurricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, Hayes DL, et al. HRS/EHRA expert consensus on the monitoring of cardiac electronic implantable devices (CIEDs) description of techniques indications, personnel, frequency, and ethical considerations. Heart Rhythm. 2008; 5: 907-925.
5. Weisberg IL, Desai S, Vose JG, Knight BP. Abstract presented from the podium at Heart Rhythm Society 2010 and Cardiostim 2010.

4. Wilkoff BL, Aurricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, Hayes DL, et al. HRS/EHRA expert consensus on the monitoring of cardiac electronic implantable devices (CIEDs) description of techniques indications, personnel, frequency, and ethical considerations. Heart Rhythm. 2008; 5: 907-925.
5. Weisberg IL, Desai S, Vose JG, Knight BP. Abstract presented from the podium at Heart Rhythm Society 2010 and Cardiostim 2010.
6. Kypta A, Blessberger H, Saleh K, Hönig S, Kammler J, Steinwender C. An electrical plasma surgery tool for device replacement--retrospective evaluation of complications and economic evaluation of costs and resource use. PACE 2014; 00:1–7.

7. Vose JG, McAdara-Berkowitz J. Reducing scalpel injuries in the operating room. AORN J. 2009;90(6):867-872.

8. Zientara A, Komminoth P, Seifert B, Odavic D, Dzemali O, Häussler A, Genoni M. Skeletonized internal thoracic artery harvesting: a low thermal damage electrosurgical device provides improved endothelial layer and tendency to better integrity of the vessel wall compared to conventional electrosurgery. J Cardiothorac Surg. 2018;13:105.

Revolution Surgical Pty Ltd
4/22 Rowood Road, Prospect NSW 2148
ABN: 63 165 643 434

© 2018-2024 Revolution Surgical

Website by: WebInjection